* If you want to update the article please login/register
We showed that deazaflavin-dependent nitroreductase could act as an activating enzyme for these new compounds in M. tuberculosis. Oral administration of compounds with extended biaryl side chains was particularly helpful in eradicating infection in an acute T. cruzi-infected murine model. These results show that effective nitroimidazopyrazinones could be marketed as orally available clinical candidates against both tuberculosis and Chagas disease.
Source link: https://europepmc.org/article/MED/36111399
In Trypanosoma cruzi infection, we present a systematic review that compiles experimental in vivo and human results. TCR Vu03b1 subfamilies were assessed in one human study, unlike TCR Vu03b2, and TCR Vu03b1 showed a more restricted usage, according to the report. Despite the high frequency of TCR Vu03b2 expression in human Chagas disease's use, a down-regulation of TCR Vu03b25 expression by T cells from patients in the acute phase of the disease was reported. It was also found that murine Vu03b29+ T cells derived from nonlymphoid organs of T. cruzi-infected animals had a modulatory profile, while splenic Vu03b29+ T cells produced inflammatory cytokines, indicating that although these cells have the same TCR Vu03b2 region use, these cells are functionally distinct.
Source link: https://europepmc.org/article/MED/36107855
We make suggestions for increasing access to Chagas disease diagnosis and treatment in the United States by showcasing screening services for Chagas disease that currently exist in endemic and non-endemic settings. Outlined are some examples of successful screening services for Chagas disease in other countries as well as in some states of the United States, including those that focus on high-risk populations and are linked to affordable and effective treatment options. Summary Given that the number of Chagas disease prevalence and even risk of transmission in the United States is on the rise, there is a need for improving detection and treatment of the disease. We specifically recommend integrating Chagas disease into pertinent medical studies, particularly in cardiology and obstetrics/gynecology, and using advocacy as a means to raise Chagas disease awareness.
Source link: https://europepmc.org/article/MED/36105114
Trypanosoma cruzi, Chagas disease's causative agent, is a true parasite with extreme genetic variation and a complicated life cycle. Here, we discuss the T. cruzi Arequipa strain as an excellent model for CD drug discovery. We characterized acute-phase parasitaemia and persistent-phase tropism in BALB/c mice and determined the susceptibility profile of the different strains' various morphological subtypes of this species in vitro and in vivo. This strain's tropism makes it an excellent example for the testing of new compounds with a potential anti-Chagas profile for this disease treatment.
Source link: https://europepmc.org/article/MED/36096184
Chagas Disease, a persistent disease caused by the Trypanosoma cruzi parasite, is a Neglected Tropical Disease endemic to Latin America. A total of 79 triatomine bugs were discovered from eight Venezuelan states, including one as Panstrongylus geniculatus, 1 as Triatoma dimidiata, 1 as Triatoma dimidiata, and 10 as Triatoma maculata. We analyzed 8 triatomine feces samples collected from 4 Panstrongylus geniculatus that had been confirmed positive by qPCR for T. cruzi. All samples were found to contain TcI, the most widely distributed and widely distributed strain of T. cruzi, according to a subsequent molecular analysis of discrete typing units. This research introduces a new Citizen Science approach that may help extend the surveillance networks for CD in endemic countries.
Source link: https://europepmc.org/article/MED/PMC9475302
Trypanosoma cruzi, a parasite that causes Chagas disease worldwide, affects 6-7 million people worldwide. NGP11b demonstrated sensitivity and specificity similar to that of tGPI-MUC from chronic CD patients from Venezuela and Mexico as well as healthy controls by chemiluminescent immunoassay using sera/plasma from chronic CD patients from Venezuela and Mexico, as well as healthy controls. A notable decrease in anti-Gal antibody reactivity to NGP11b was found during preliminary examination of CCD patients subjected to chemotherapy. According to our results, NGP11b is a potential BMK for diagnosis and treatment evaluation in CCD patients.
Source link: https://europepmc.org/article/MED/36080480
Chagas disease treatment and prevention are limited and underutilized. We'll talk about the initiation of a series of benzoxaborole polymers with nanomolar activity against T. cruzi's extra- and intracellular phases. AN15368 was found to be infectious in vitro and in vivo against a variety of genetically distinct T. cruzi lineages, and was largely curative in non-human primates with long-term naturally acquired infections.
Source link: https://europepmc.org/article/MED/36065062
The present systematic review and meta-analysis of diagnostic tests aims to highlight the results of literature over the last three years for the diagnosis of Chagas disease. This study sought to determine the accuracy of diagnostic methods for CD in the disease's acute and chronic phases. According to this meta-analysis, ELISA and qPCR techniques provided a better result than other methods of diagnosing CD in the chronic and acute phases, respectively. Compared to serological and molecular examinations, the ELISA diagnostic test obtained the highest success in diagnosing acute and chronic CD by means of the AUC's tightly controlled false positive rates. Future studies on new CD diagnostics technologies should be targeted.
Source link: https://europepmc.org/article/PPR/PPR539907
People with human immunodeficiency virus infection are vulnerable to serious sequelae, particularly the Trypanosoma cruzi reactivation virus. Patients with high CD4 cell counts and acute neurologic or cardiac signs that have elevated neurological or cardiac signs should be tested and treated immediately; these patients should be promptly assessed and treated. One of the ways to evaluate at-risk PWH and thus minimize T. cruzi-related morbidity and mortality is to include Chagas disease testing into the panel of tests commonly administered during the entry-to-care evaluation for at-risk PWH.
Source link: https://europepmc.org/article/MED/35180299
In the subtropical areas of Loja Province, Ecuador, this research was designed to determine the effectiveness of selective and community-wide insecticide spraying to control triatomines. In each of the four visits, out of the 130 domestic units visited, 41 domestic units were examined. Spraying with 5% deltamethrin was used in selective and community-wide insecticide applications, as shown by the 25 mg/m2 active ingredient. The likelihood of infestation decreased by 62% and 51%, respectively, after one and two rounds of selective insecticide spraying. Trypanosoma cruzizi infection in triatomines increased overtime, from 2008 to 2012, according to Trypanosoma cruzi. Neither of the two spraying techniques was particularly effective in triatomine control in this region, and our findings point to a high likelihood of re-infestation after insecticide application.
Source link: https://europepmc.org/article/MED/36044033
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions